What novel therapies are under investigation for the treatment of high-risk MPN?

During the ESH 10th Translational Research Conference: Myeloproliferative Neoplasms, the MPN Hub spoke to Prithviraj Bose, MD Anderson Cancer Center, Houston, US. We asked, What novel therapies are under investigation for the treatment of high-risk MPN?
Bose provides an overview of novel therapies for high-risk MPN, beginning with a discussion on spleen response and adverse events from the phase III MANIFEST-2 (NCT04603495) and TRANSFORM-1 (NCT04472598) trials investigating pelabresib and navitoclax in combination with ruxolitinib. Then, he reviews combination therapies, summarizing the current status of selinexor and vorinostat in combination with ruxolitinib as first-line and add-on treatments. Finally, Bose discusses the role of cellular and immunotherapies, such as JNJ-88549968 and AJ1-10502, to minimize the risk of cytopenias; he also highlights emerging treatments of interest.